$19.95 Buy and instantly download this paper now
The paper discusses the risk factors for breast cancer that include age, gender, family history, genetic defects, early menses/late menopause, alcohol consumption and age at childbirth. The paper dispels the myths about breast cancer risks and then explains why breast self-examination is so important. The paper outlines the tests that can be done and discusses what factors can lower the risk of this cancer. Then, the paper addresses the option of medical preventative care in the form of medication which is done in cases of exceptionally high risk. The paper concludes that through education and discourse, great gains have been made in the battle against breast cancer.
From the Paper:"Simply defined, breast cancer is any cancer that starts in breast tissue. There are two primary types: ductal (which starts in the ducts that conduct milk to the nipple) and lobular (which starts in the lobes that produce milk). Rarely, cancer starts in other areas of the breast. With some breast cancers, the hormone estrogen can cause cancer tumors to increase in size; these are called ER (estrogen receptor positive) cancers. Another type of breast cancer is HER2-positive; the HER-2 gene helps cells regenerate, and, the more strands of HER-2 in a cell (including a cancer cell), the faster it will grow. There is evidence that HER2-positive breast cancer is more aggressive than other types, and more likely to recur after treatment."
Sample of Sources Used:
- Brinker, N.G. (2005). The Battle against Breast Cancer. USA Today: Society for the Advancement of Education, 134(2722):31.
- Saslow, D., Boetes, C., and Burke, W. (2003) American cancer society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin, 57(2):75-89.
- Lehman, C.D., Gatsonis, C, Kuhl, C.K. (2007). MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med, 356(13):1295-303.
- Piccart-Gebhart, M.J., Procter, M., and Leyland-Jones, B. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 20;353(16):1659-72.
- Romond, E.H., Perez, E.A., and Bryant, J. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 353(16):1673-84.
Cite this Term Paper:
Breast Cancer (2010, February 11) Retrieved June 06, 2020, from https://www.academon.com/term-paper/breast-cancer-118627/
"Breast Cancer" 11 February 2010. Web. 06 June. 2020. <https://www.academon.com/term-paper/breast-cancer-118627/>